Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Headquartered in Bridgewater, New Jersey, we are advancing the next generation of cell therapy through a portfolio of innovative technologies, including autologous, allogeneic, and in vivo cell therapy approaches. Our research spans chimeric antigen receptor T-cell (CAR-T), T-cell receptor (TCR-T), natural killer (NK) cell-based therapies, and other emerging platforms designed to transform the treatment of serious diseases. From our global network of research and development sites, we are committed to discovering and developing safe, effective, and cutting-edge therapies for patients worldwide.

Legend Biotech entered into a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). Through this strategic partnership, we combine complementary expertise and capabilities to advance innovative immunotherapies for patients living with multiple myeloma.

Legend Biotech is seeking an Executive Director, Multiple Myeloma Pipeline Lead as part of the Clinical Development team based in Somerset, NJ.

Role Overview

The Executive Director, Clinical Development, will provide strategic, scientific, and medical leadership for Legend Biotech’s Multiple Myeloma Pipeline. This individual will serve as the clinical lead for the Multiple Myeloma Pipeline and will be accountable for defining and executing an integrated clinical development strategy across a portfolio of assets and programs spanning early-stage and, as appropriate, late-stage development. The role includes leadership of first-in-human, dose-escalation, dose-expansion, proof-of-concept, and registration-enabling clinical studies across the pipeline. The Executive Director will collaborate closely with cross-functional teams to support pipeline prioritization, asset differentiation, regulatory strategy, lifecycle planning, and evidence generation. Responsibilities include supporting IND submissions and regulatory interactions; integrating translational, biomarker, pharmacology, safety, and clinical data; and providing strategic input into study design, clinical operations, and development decision-making.

Ultimately, this individual will be responsible for generating high-quality clinical evidence that enables data-driven pipeline decisions, supports benefit-risk assessments, establishes competitive differentiation, and advances programs toward registration and commercialization. The successful candidate will bring deep expertise in multiple myeloma, strong clinical judgment, experience advancing innovative cellular and immunotherapyplatforms, and the ability to lead effectively in a highly matrixed, fast-paced environment.

Serve as the clinical lead for the Multiple Myeloma Pipeline, providing strategic, scientific, and medical leadership across the development lifecycle.
Develop and maintain an integrated clinical development strategy across the Multiple Myeloma Pipeline, ensuring alignment with corporate objectives, scientific opportunities, competitive positioning, regulatory expectations, and patient needs.
Drive pipeline prioritization, asset sequencing, resource-allocation recommendations, and development-stage decision-making across multiple assets, programs, disease settings, and lifecycle opportunities.
Develop and execute integrated clinical development plans, including disease-setting and line-of-therapy strategy, patient population selection, endpoint strategy, dose-selection rationale, sequencing and combination strategy, biomarker and measurable residual disease strategy, safety monitoring approach, and evidence-generation plans.
Lead the design, execution, monitoring, interpretation, and reporting of first-in-human, dose-escalation, dose-expansion, proof-of-concept, and other early clinical studies.
Lead or contribute to late-stage clinical development activities, as appropriate, including pivotal-study strategy, comparator and endpoint selection, protocol design, data interpretation, and registration-enabling planning.